Cutaneous interstitial fluid protein concentrations in the inflammatory syndrome: Pharmacological consequences

Suction blister fluid as potential body fluid for biomarker proteins

“…For several diseases, including epidermal necrolysis [9], scleroderma [10], and CRPS1 [6], suction blister fluid has been used as a source to identify/ quantify potential biomarkers. In these cases and in other studies [11][12][13][14], the variations of protein contents measured in suction blister fluid samples were demonstrated to be sufficient for reliable measurement of biomarkers. Suction blister fluid has not been studied in depth at the proteome level yet and may thus be a potential new body fluid to be used for diagnosis of coetaneous diseases.…”

Enhanced and Sustained Cutaneous Delivery of Vismodegib by Ablative Fractional Laser and Microemulsion Formulation

“…However, in vivo, more than 99% of vismodegib remains bound to plasma proteins, mainly a 1 -acid glycoprotein (Giannetti et al, 2011;Graham et al, 2011). This protein is also present in the interstitial fluid, although at substantially lower concentrations (Clerc et al, 1990). We believe that currently the best surrogate marker for clinically relevant levels of vismodegib is average steady-state total concentrations for patients treated with oral vismodegib, which may range from 5.5e56.0 mmol/liter, which is consistent with concentrations necessary to inhibit growth of BCC cells (Graham et al, 2011;Olesen et al, 2017).…”

Issues in Pharmacokinetics and Pharmacodynamics of Anti-Infective Agents: Distribution in Tissue

“…Therefore, there are many available data on the penetration of various antibiotics into cantharis-or suction-induced skin blister fluid (9,17,19,23,30,60,71,111,137,138,146 ). These studies were justified by the notion that "skin blister fluid levels are closer to the biophase than blood" (138).…”

“…69: P61). Furthermore, a direct comparison with newer technologies revealed that SBS has many methodological disadvantages (19,23,30,60).…”